NovaSpira gets FDA clearance to start U.S. trial of NS-342

NovaSpira Biotherapeutics said the FDA accepted its IND for NS-342, clearing the way for a U.S. Phase 1 study in advanced hepatocellular carcinoma and other GPC3-positive solid tumors. The move gives the company a clinical path for a bispecific immunotherapy aimed at tumors with limited treatment options.

Why it matters: - The FDA acceptance opens the door for NovaSpira Biotherapeutics to begin U.S. clinical development of NS-342. - The drug is aimed at advanced hepatocellular carcinoma, where patients often have few effective options after first-line therapy. - NovaSpira is also positioning NS-342 for other GPC3-expressing solid tumors, including liver and lung cancers.

What happened: - NovaSpira Biotherapeutics said the U.S. Food and Drug Administration accepted its Investigational New Drug application for NS-342. - The IND submission was received on Sept. 8, 2026. - The acceptance enables initiation of clinical development in the United States. - The company announced the milestone on Oct. 12, 2026.

The details: - NS-342 is a next-generation GPC3 x 4-1BB bispecific biologic. - The molecule is designed to activate immune responses inside the tumor microenvironment while limiting systemic toxicity. - The planned U.S. Phase 1 study will assess safety, tolerability, pharmacokinetics, immune activation and preliminary antitumor activity. - NS-342 was previously known as PRS-342 and BOS-342. - NovaSpira describes NS-342 as a GPC3 × 4-1BB bispecific protein. - Preclinical data showed T-cell activation and tumor cell lysis that depended on the presence of GPC3-positive tumor cells. - Preclinical work also showed increased IL-2 production, TIL infiltration in tumors in HCC xenograft mice and antitumor activity. - NovaSpira is a clinical-stage biotechnology company focused on next-generation immunotherapies for solid tumors with high unmet need.

Between the lines: - The IND acceptance gives NovaSpira a regulatory green light, but the real test now shifts to human safety and early efficacy data. - The company is targeting a biologically selected patient group, which could help sharpen the case for a bispecific approach if early results hold up. - NovaSpira is making a broader bet that GPC3-targeted immune activation can work across multiple solid tumors, not just liver cancer. - The company’s forward-looking language signals that execution risk remains high, as with most early-stage cancer drug programs.

What's next: - NovaSpira plans to launch the U.S. Phase 1 study of NS-342. - Early readouts will focus on safety and tolerability before any judgment on antitumor activity. - Further development will depend on whether the drug shows enough immune activation and early clinical signal to justify later-stage testing.

The bottom line: - NovaSpira has cleared a key regulatory hurdle, but NS-342 still has to prove itself in patients.